Non-invasive Blood Glucose Evaluation And Monitoring (BGEM) Technology For Diabetic Risk Assessment
The latest Singapore National Population Health Survey has reported a concerning diabetes trend. From 2019-2020, 9.5% of the adults had diabetes, slightly dropping to 8.5% from 2021-2022. About 1 in 12 (8.5%) of residents aged 18 to 74 were diagnosed, with an age-standardised prevalence of 6.8% after accounting for population ageing. Among the diabetes patients, close to 1 in every 5 (18.8%) had undiagnosed diabetes, and 61.3% did not meet glucose control targets. Prediabetes is also prevalent, with 35% progressing to type 2 diabetes within eight years without lifestyle changes.
Untreated Type 2 diabetes can lead to severe health issues. Tackling this challenge requires a holistic approach, focusing on awareness, early diagnosis, and lifestyle adjustments for diabetes and prediabetes. Recognising the need for innovation to address this, the technology owner develops a cost-effective and non-invasive AI-powered solution, Blood Glucose Evaluation And Monitoring (BGEM), that detects glucose dysregulation in individuals to monitor and evaluate diabetic risks.
BGEM allows users to track their blood glucose levels regularly, identify any adverse trends and patterns, and adopt early intervention and lifestyle changes to prevent or delay the onset of diabetes. Clinically validated in 2022, with a research paper published in October 2023, the technology is open for licensing to senior care/home care providers, telehealth platforms, health wearables companies, and more.